Immunotoxins: all 376 studies that test it
Page 3 of 4. Open to participants first (65), then studies with results posted, then the rest; newest registration first within each.
- Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)CompletedNCT00299494Phase 1/2Results posted
- Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic SyndromesCompletedNCT00274781Phase 2Results posted
- Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or MyelodysplasiaCompletedNCT00136084Phase 3Results posted
- S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AMLCompletedNCT00085709Phase 3Results posted
- Study Evaluating CMC-544 In B-Cell Non-Hodgkin's LymphomaCompletedNCT00073749Phase 1Results posted
- Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung CancerCompletedNCT00065429Phase 1/2Results posted
- HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerTerminatedNCT06595563Phase 2
- A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive, not recruitingNCT06316531Phase 3
- A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerActive, not recruitingNCT06265428Phase 3
- PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive, not recruitingNCT05922904Phase 2
- Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AMLTerminatedNCT05716009Phase 1
- Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction ChemotherapyActive, not recruitingNCT05456698Phase 2
- Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
- Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis FungoidesSuspendedNCT05414500Phase 1
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingNCT05323955Phase 2
- Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT05303792Phase 2
- A Safety Study of Brentuximab Vedotin in Participants With HIVWithdrawnNCT05244473Phase 1
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- Open Label Extension Study of Brentuximab Vedotin in Early dcSScCompletedNCT05149768Phase 2
- Venetoclax Plus Inotuzumab for B-ALLActive, not recruitingNCT05016947Phase 1
- Brentuximab Vedotin in Combination With CHEP in Patient With PTCLStatus unknownNCT05006664Phase 2
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
- Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid LeukemiaCompletedNCT04915612Phase 1
- Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSTerminatedNCT04849910Phase 1/2
- Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2
- Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerActive, not recruitingNCT04733118Phase 2
- De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeTerminatedNCT04675827Phase 2
- Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2
- Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast CancerWithdrawnNCT04419181Phase 2
- Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell LymphomasWithdrawnNCT04334174Phase 2
- Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04207190Phase 1
- Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerTerminatedNCT04042051Phase 1
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
- Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic LeukemiaTerminatedNCT03913559Phase 2
- CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT03904251Phase 1
- Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaCompletedNCT03900949Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic LeukemiaWithdrawnNCT03851081Phase 1/2
- Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03848754Phase 1
- T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingNCT03755804Phase 2
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaActive, not recruitingNCT03712202Phase 2
- Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedNCT03672539Phase 2
- Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT03652441Phase 2
- Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT03610438Phase 2
- BV After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03540849Phase 2
- OPTmizing Advanced Stage HodgkIn LymphoMa patIentS TherapyStatus unknownNCT03527628Phase 2
- Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With GemcitabineCompletedNCT03496779Phase 2
- Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)Status unknownNCT03474133Phase 2
- Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseaseActive, not recruitingNCT03441061Phase 2
- A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerTerminatedNCT03429101Phase 1
- Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.Status unknownNCT03418558Phase 2
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
- Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
- Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALLCompletedNCT03249870Phase 2
- Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal CancerStatus unknownNCT03225937Phase 2
- CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.CompletedNCT03217643Phase 2
- Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
- Kadcyla In pAtients With bRAin MetastasisWithdrawnNCT03203616Phase 2
- Brentuximab Vedotin in Early Diffuse Cutaneous Systemic SclerosisCompletedNCT03198689Phase 2
- Brentuximab Vedotin and BeEAM High-dose Chemotherapy in LymphomasSuspendedNCT03187210Phase 1/2
- Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast CancerCompletedNCT03153163Phase 1
- Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03084939Phase 3
- Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT03013933Phase 1
- Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by SurgeryActive, not recruitingNCT03007030Phase 2
- TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary SyndromeCompletedNCT02822586Phase 1
- Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid MalignanciesWithdrawnNCT02780011Phase 1
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02734771Phase 2
- Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
- Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast CancerWithdrawnNCT02725541Phase 2
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingNCT02724163Phase 3
- Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICECompletedNCT02686346Phase 1/2
- Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersCompletedNCT02675829Phase 2
- HD21 for Advanced StagesActive, not recruitingNCT02661503Phase 3
- A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell LymphomaCompletedNCT02616965Phase 1
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
- Neoadjuvant Response-guided Treatment of HER2 Positive Breast CancerActive, not recruitingNCT02568839Phase 2/3
- A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidityCompletedNCT02567851Phase 2
- Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage SettingTerminatedNCT02499627Phase 2
- Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL PatientsCompletedNCT02497131Phase 2
- Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4CompletedNCT02473146Phase 2/3
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCLTerminatedNCT02462538Phase 1/2
- Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)WithdrawnNCT02408042Phase 1/2
- Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT02338050Phase 2
- Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
- Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDCompletedNCT02298283Phase 2
- Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.CompletedNCT02292979Phase 2
- Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsStatus unknownNCT02280993Phase 1
- Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin LymphomasCompletedNCT02280785Phase 2
- Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin LymphomaStatus unknownNCT02275598Phase 2
- Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaTerminatedNCT02254239Phase 1
- Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or EsophagusTerminatedNCT02254044Phase 1
- Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast CancerTerminatedNCT02254031Phase 1
- Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT02254018Phase 1
- Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast CancerCompletedNCT02254005Phase 1
- BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEVCompletedNCT02244021Phase 2
- Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02243436Phase 1/2